Breast Cancer Combo May Spare Some Chemotherapy
In a small phase 2 trial, immune-positive HER2-negative patients often avoided anthracycline chemotherapy after treatment.
Updated on Nov. 6, 2026 in Cancer

A phase 2 trial called I-SPY2.2 reported promising early activity for rilvegostomig combined with trastuzumab deruxtecan (RT-DXd) in patients with immune-positive, HER2-negative early breast cancer. Among immune-positive patients who achieved pathologic complete response, most avoided standard anthracycline-based chemotherapy.
Why it matters
For people with high-risk early breast cancer that is HER2-negative, new options that might reduce reliance on chemotherapy before surgery could change treatment planning in future. The results are early and come from a small phase 2 study, so they are a signal to watch rather than a change in current care.
This phase 2 adaptive randomized trial enrolled 377 eligible patients with high-risk stage II/III HER2-negative early breast cancer, including HER2-low and HER2-ultralow tumors. Among immune-positive patients who achieved pathologic complete response, 97% avoided anthracycline-based chemotherapy, but the study was small and results are preliminary.
The players
I-SPY2.2 trial
A multi-arm adaptive neoadjuvant breast cancer trial that tests novel treatment combinations before surgery in high-risk patients.
The details
Patients were adaptively randomized and stratified by hormone receptor status and response-predictive subtypes, then received up to three sequential treatment blocks based on their response and subtype. The approach pairs a topoisomerase-1-inhibiting antibody-drug conjugate with a PD-1 checkpoint inhibitor, a combination researchers believe may improve immunotherapy efficacy. The most common side effects were fatigue and nausea, while six serious adverse events occurred, including three cases of pulmonary embolism and three of interstitial lung disease.
Timeline
The I-SPY2.2 trial results were reported as a phase 2 analysis; the specific publication or presentation date was not stated in the source.
Health Landscape
Pathologic complete response has become a key early marker in neoadjuvant breast cancer research, and the I-SPY2.2 platform is testing whether newer antibody-drug conjugates combined with immunotherapy can reduce chemotherapy exposure. Whether such combinations reach standard-of-care use will depend on confirmation in larger trials.
If you have been diagnosed with early breast cancer, this research is worth discussing with your oncology team as an example of emerging options that may change future treatment planning. Right now, standard care decisions remain with your physician, and this early result is not yet a reason to change your plan.
The takeaway
Early results suggest combining an antibody-drug conjugate with immunotherapy may spare some patients chemotherapy, though these findings are preliminary and come from a small trial. Anyone with breast cancer can ask their oncologist which current options and clinical trials are appropriate for their specific tumor type.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Derm Immuno Today.


